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Light-based therapeutic and imaging modalities, which emerge in clinical applications, rely on molecular
tools, such as photocleavable protecting groups and photoswitches that respond to photonic stimulus
and translate it into a biological effect. However, optimisation of their key parameters (activation
wavelength, band separation, fatigue resistance and half-life) is necessary to enable application in the
medical field. In this perspective, we describe the applications scenarios that can be envisioned in clinical
practice and then we use those scenarios to explain the necessary properties that the photoresponsive
tools used to control biological function should possess, highlighted by examples from medical imaging,
drug delivery and photopharmacology. We then present how the (photo)chemical parameters are
currently being optimized and an outlook is given on pharmacological aspects (toxicity, solubility, and
stability) of light-responsive molecules. With these interdisciplinary insights, we aim to inspire the future
directions for the development of photocontrolled tools that will empower clinical applications of light.lse Welleman was born in Del,
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911. Introduction
The use of light as a tool for imaging and external control for
processes in the human body offers unparalleled bio-
orthogonality and spatiotemporal precision.1 These advan-
tages have been recognized through the use of light in optical
imaging, where light in visible and near-infrared (NIR) regions
of the electromagnetic spectrum is used to image the distribu-
tion of dedicated tracers in the human body, and in photody-
namic therapy, where photosensitizers generate reactive oxygenDr. Mark Hoorens was born in
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View Article Onlinespecies (ROS) upon irradiation with light, which is used in
cancer treatment. While these applications in therapy and
imaging already present a proof-of-principle for the use of light
in the hospital setting, we expect that the recent developments
in the design and synthesis of photoresponsive molecules will
greatly expand the repertoire of clinical modalities, through
enabling the use other photochemical processes such as photo-
isomerization and photo-cleavage. These light-based
approaches will empower drug delivery (nanomedicine), pho-
topharmacology and molecular imaging and will play an
important role in modern medicine, allowing for precise and
personalized treatment.
In this perspective, we present the recent developments in
the eld of photoresponsive molecular tools, including photo-
switches and photocleavable protecting groups (PPGs), from the
perspective of their future medical applications, with special
attention to their key (photo)chemical and pharmacologicalBen L. Feringa obtained his PhD
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This journal is © The Royal Society of Chemistry 2020properties. We outline the therapeutic and diagnostic scenarios
enabled by those tools and propose how their different prop-
erties predispose them to be used in a certain application.
Furthermore, we dene the key pharmacological aspects that
the research on photoresponsive tools should take into
consideration in its further development. Finally, we highlight
the opportunities and challenges of molecular approaches
towards future application of light in medicine, using examples
from medical imaging, drug delivery and photopharmacology.2. Photoresponsive molecular tools
The molecules discussed here can be categorised in two main
classes: photoswitches and photocleavable protecting groups
(PPGs) (Fig. 1). What sets them apart is the key photochemical
process that they can undergo once promoted to the excited
state with light irradiation. While for photoswitches the change
in molecular structure is photochemically or thermally revers-
ible, PPGs rely on the irreversible breaking of a s bond between
them and the leaving group of their cargo.2.1 Molecular photoswitches2–5
Molecular photoswitches are dened as chemical structures
that consists of two or more isomers, that can be interconverted
using light irradiation. The photoisomerization of molecular
photoswitches proceeds via two basic mechanisms: trans to cis
isomerization and 6p electrocyclization of a triene system
(Fig. 1). Azobenzenes6 and their heteroaromatic analogues,7
indigos,8 hemithioindigos,9 stilbenes,10 hydrazones,11 and imi-
nothioindoxyls12 undergo the double bond isomerisation, while
diarylethenes13 switch via the 6p electrocyclization. Spiropyr-
ans14 follow a mixed mechanism, as they rst undergo 6p
electrocyclization, and later the trans–cis isomerization takes
places. On the other hand, donor–acceptor Stenhouse adducts
(DASAs)15 and fulgides16 rst undergo a trans–cis isomerization,
which is followed by a electrocyclization (Fig. 1). Another way to
classify photoswitches is to consider the thermal barrier forWiktor Szymański received his
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Fig. 1 Overview of the photoresponsive molecules for emerging biomedical applications. In blue is shown the metastable state (photoswitches)




























































































View Article Onlinetheir re-isomerisation: if the barrier is relatively high, both
forms are kinetically stable, and their interconversion is
possible only with light (P-type switches). For low barriers, the
thermal isomerisation from themetastable (MS) to the stable (S)
form will take place (T-type switches). In all cases, the isomer-
isation results in light-induced modulation of the key proper-
ties, such as polarity and geometry. These changes can be used
for controlling the behaviour of molecular photoswitches and
their derivatives in a biological context.Fig. 2 Key properties of light-responsive tools for biomedical applicatio
groups (PPGs, c). (a) Idealized UV-Vis spectra of the stable (S) and me
separation that enables selective addressing of isomer with light of appro
a molecular photoswitches. (1) Switching from the stable to metastable s
stable state using light of l2 wavelength. (3) In the dark, the system relaxes
a first-order process, which proceeds with a kinetic constant that depend
irradiation wavelength 3 and quantum yield for the uncaging process f.
11674 | Chem. Sci., 2020, 11, 11672–11691Fig. 2 presents the key parameters of molecular photo-
switches that are relevant to their biomedical applications and
that further-on are used to categorize the structures for their
applicability in different biomedical scenarios. The idealized
UV-Vis spectrum of a molecular photoswitch (Fig. 2a) shows
a band separation that enables selective addressing of isomers
with light of distinct wavelengths (l1 and l2). For switching from
the stable to metastable state (Fig. 2b(1)) using light of l1
wavelength, the kinetic constant k1 of this process mostly
depends on the light intensity I, molar attenuation coefficient ofns: molecular photoswitches (a and b) and photocleavable protecting
tastable (MS) isomers of a molecular photoswitch, showing the band
priate wavelengths (l1, l2). (b) Stages of light-induced isomerisation of
tate using light of l1 wavelength. (2) Switching from the metastable to
to the thermal equilibrium. (c) Uncaging of PPG-modified compound is
s on the light intensity I, molar attenuation coefficient of the PPG at the



























































































View Article Onlinethe stable form at l1 (3(S, l1)) and quantum yield for the
switching from S to MS fS/MS. In time, a photostationary state
(PSS(l1)) is reached, at which the isomerisation in both direc-
tions proceeds with the same rate. At PSS, the metastable
isomer is enriched, and it is characterised by photostationary
state distribution (PSD(MS)) of isomers. Assuming long half-life
of the metastable isomer, the content of MS at PSS(MS) depends
on the ratio of 3(S, l1)  fS/MS and 3(MS, l1)  fMS/S, which
represent the efficiency of switching in forward and reverse
directions, respectively.
Switching back from the metastable to stable state
(Fig. 2b(2)) can be achieved using light of l2 wavelength. The
kinetic constant k2 of this process mostly depends on the light
intensity I, molar attenuation coefficient of the metastable form
at l2 3(MS, l2) and quantum yield for the switching fromMS to S
fMS/S. In time, a photostationary state (PSS(l2)) is reached, in
which the stable isomer is enriched, and which is characterised
by photostationary state distribution (PSD(S)) of isomers.
Assuming long half-life of the metastable isomer, the content of
S at PSS(S) depends on (3(MS, l2)  fMS/S)/(3(S, l2)  fS/MS).
In case of the T-type switches, another re-isomerisation
pathway is also possible (Fig. 2b(3)). In a thermal process, the
system relaxes to the thermodynamic equilibrium, which in
most cases consists exclusively of the stable form. This process
is characterised by a certain half-life t1/2 ¼ ln(2)/kt, where kt is
the kinetic constant of the thermal MS / S isomerisation,
which depends on the free enthalpy of activation associated
with this process DG‡ and the temperature T.
The ideal properties for a photoswitch (appropriate half-life,
photoswitching kinetics, photostationary state distribution of
the isomers (PSD) and biological activity) depend heavily on the
desired application. However, there are some universal key
properties of both photoswitches that are required in biological
and biomedical setting. Firstly, they should respond to irradi-
ation with low energy red to near infrared (NIR) light (650–
900 nm, so called phototherapeutic window), to enable pene-
tration of light through the skin and into tissue,1,17 and avoid
the toxicity of carcinogenic UV light.18,19 Secondly, photo-
switches should also be nontoxic, biologically stable and resis-
tant against photodegradation (fatigue). Furthermore, building
a photoswitch into e.g. a pharmacologically active substance
should not induce its toxicity or dramatically change its original
properties. These last four general key parameters are discussed
in depth later (Section 7).2.2 Photocleavable protecting groups (PPGs)20
The application of a PPG relies on transiently blocking the
function of a compound, which is restored aer irradiation with
light through irreversible bond cleavage. The PPGs discussed in
this review are of the following types: 4-nitrobenzyl (oNB) and
coumarin derivatives, BODIPY-type PPGs and amino-1,4-
benzoquinone-based systems (Fig. 1).
Deprotection of a PPG-modied compound is a rst-order
process, which proceeds with a kinetic constant that depends
on the light intensity I, molar attenuation coefficient of the PPG
at the irradiation wavelength 3 and quantum yield for theThis journal is © The Royal Society of Chemistry 2020uncaging process f (Fig. 2c). The product of 3 and f is known as
the uncaging cross section and is a good measure of the effi-
ciency of the process, as it takes into account both the proba-
bility of molecule entering the excited state and the probability
of photocleavage taking place. High uncaging cross section
means that light of lower intensity is sufficient for activation,
which is a key concern in strongly attenuating media such as
human tissue.
Additional requirements for the use of PPGs in medical
applications include the following: (i) activation wavelength in
the phototherapeutic window, (ii) clean deprotection to bio-
logically benign products20 (iii) solubility and stability in
aqueous solutions.3. Scenarios for application of
photocontrolled tools in medicine
The specic application of the photoresponsive molecule
dictates the requirements regarding activation wavelength,
photostationary state distributions, photochemical conversion
efficiency and the half-life of the metastable state (Fig. 2).
However, it is important to note that there is not one privileged
combination of those parameters, and depending on the
application, certain scenarios can be dened (Fig. 3) that rely
upon different photoswitch properties. In the following, we
outline those scenarios and then discuss the optimisation of
each key parameter discussed separately with reported
examples.3.1 Scenario 1
In this scenario (Fig. 3), the photoresponsive molecule is acti-
vated before the administration to the human body. Once
administered, it slowly loses its activity through thermal relax-
ation and is then excreted in its inactive state.
The prerequisites for this scenario are the MS state being
more active in the biological system and having the half-life in
the hour range, to make sure the photoresponsive molecule is
still active upon arrival at the desired site. Since the irradiation
happens outside the body before drug administration, wave-
lengths outside of the phototherapeutic window can be used for
activation. A key parameter in this scenario, similarly to
scenarios 2–4, is the activity difference between the two pho-
toisomers. Idealized case (Fig. 3) assumes a large difference,
therefore the photostationary state distribution (PSD(MS)) for
the active form does not necessarily need to be high to enable
a pronounced difference in biological response. However, more
realistically, this high difference in activity between the isomers
is difficult to achieve. Here, the PSD of the metastable active
form should be high to still have impact. Photoresponsive
molecules that full these requirements are most of the T-type
photoswitches with half-lives in the range of hours, including
certain types of azobenzenes,6 hemithioindigos9 and
spiropyrans.14
Scenario 1 is useful in cases where one aims at limiting the
exposure of the environment to the biologically active
substance. This is especially important in e.g. antibioticChem. Sci., 2020, 11, 11672–11691 | 11675
Fig. 3 Therapeutic scenarios, for the use of reversibly (1–4) and irreversibly (5) photocontrolled systems for medical application, concerning the
situations when the compound is to be activated outside (1) or inside (2–5) of the body, and taking into consideration if the stable (3) or
metastable (1, 2 and 4) form of the switch is more active in the biological system. The intensity of colour in the background of the graphs
represents the increasing biological activity that can be explored with changing the concentration of the metastable isomer (blue line). See



























































































View Article Onlinetherapy, where the presence of active antimicrobial agents in
soil and fresh water has been shown to lead to emergence and
spread of bacterial resistance. This has driven the development
of photoswitchable antibiotics,21 in the design of which the
criteria of the metastable form being more potent and having
hour-long half-lives have been taken into account. Velema et al.
envisioned an example of this scenario, where the quinolone-
based azobenzene derivative was activated with 365 nm to the
cis form (Fig. 4, compound 1). The antibacterial activity was
reduced when the active cis form reverted thermally to the less
potent trans form with a half-life of 2 hours.213.2 Scenario 2
In this scenario (Fig. 3), a photoresponsive molecule is inactive
in its thermally stable (S) state, in which is administered to the
human body and switched to the active form at the target site.
Outside of the irradiated volume, it switches spontaneously
back to the inactive state in a fast, thermal process. This
scenario allows for the highest level of control over the active
photo-isomer compared to other scenarios, and thus represents
a preferred situation for numerous applications.
The key aspect for this scenario is the short half-life, which is
used to inactivate the molecule outside of its intended action11676 | Chem. Sci., 2020, 11, 11672–11691site, rendering the PSD of the thermally stable state (PSD(S))
unimportant. Furthermore, light is used for switching in vivo in
one direction, meaning that only one wavelength used for
operation has to be in the red-NIR range. However, especially
when there is no high fold difference in activity between the two
forms, the PSD of the metastable state should be high to ensure
the biological impact. Fig. 5 presents the consequences of sub-
optimal photoswitch performance for scenario 2 (Fig. 5a).
Insufficient forward photoswitching cross section (Fig. 5b) may
lead to limited exposure of the target to activated compound or
even prevent reaching the PSD, as the forward switching
competes with fast thermal re-isomerisation. Low PSD(MS)
(Fig. 5c) may result in limited difference of biological effect
evoked by irradiation, especially when the difference in potency
of photo-isomers is small. Finally, slow thermal re-
isomerisation (Fig. 5d) leads to the unnecessary or even harm-
ful exposure of the body to the active form.
Photoswitches that could full all those requirements are
still scarce. Azonium species derived from protonation of tetra-
ortho-methoxy-azobenzenes respond to red-NIR irradiation and
show half lives in the micro secondo range,22,23 making them
compounds-of-choice for this application. DASAs show absor-
bance in the 450–700 nm region and half-lives in the sec-min
regime, but their function is compromised in aqueousThis journal is © The Royal Society of Chemistry 2020
Fig. 4 Azobenzene-derived photoswitchable antibiotic 1. (a) Compound trans-1 is a weakly potent antibiotic, which can be isomerized to its
more active cis-1 form using UV irradiation. (b) The cis form has a half-life of 2 h, and isomerizes back to the trans form, in a first order process
characterised by the recovery of the absorbance band at 368 nm. (c) Freshly activated antibiotic 1 prevents the bacterial growth, as indicated by
the lack of increase of optical density in bacterial culture in time. Increasing the time between activation and addition to bacterial culture (0–3 h)
results in partial thermal re-isomerisation to the less active trans-1 isomer and is accompanied by the drop in potency to inhibit bacterial growth.
After 3 h, the sample loses its potency and behaves the same as the negative control. Reproduced from ref. 21 with permission from Springer
Nature, Copyright 2013.
Fig. 5 Key photoswitch parameters for scenario 2. (a) Light- and
temperature-induced changes in the content of the metastable, bio-
logically active isomer (ideal situation). In panels (b–d), consequences
of insufficient photoswitching cross section (panel b), PSD(MS) (panel



























































































View Article Onlineenvironment.15 N,N-Disubstituted indigos can be isomerised at
500–670 nm, and re-isomerize on the sec-min timescale, but
again their water solubility is a limitation.24 Finally, the recently
reported iminothioindoxyls show millisecond-range half-lives
and stability/solubility in aqueous media, but their absorption
bands reach only to the green range of the UV-Vis spectrum.12
Scenario 2 is useful in cases where short half-life is sufficient
and highly localized action is warranted, for example in triggering
the neuronal response by regulating the action of ion channels.
Broichhagen et al. showed an example of an azobenzene for the
control of pancreatic beta cell function (Fig. 6, compound 2).This journal is © The Royal Society of Chemistry 2020Upon irradiation with 560 nm light, the inactive trans isomer is
switched to the active cis form, which quickly relaxes back to the
trans form (half-life is in a millisecond time range).253.3 Scenario 3
While the cases, in which the metastable (MS) isomer is the
more active one, are preferred (see scenario 2), the azologisation
of at, biologically active molecules oen results in a light-
controlled drug in which the stable (S) photo-isomer is more
potent.26 In those situation, scenario 3 (Fig. 3) is particularly
useful, in which the photoresponsive molecule is switched off
by irradiation (l1) before administration to the human body.
Aer it is reaching the target site, it is switched back (l2) to its
active form. Around the target site, the photoresponsive mole-
cule is switched back (l1) to its inactive form, to prevent non-
selective action while it is being excreted from the body.
Besides the higher activity of the stable form, the other
requirement for this scenario is the long half-life (or even the
use of a P-type switch), which is needed to ensure that the
photoresponsive molecule does not switch back to the active
form, which would lead to undesired side effects. Furthermore,
the activation wavelengths required for the both the activation
and inactivation should ideally be in the red/NIR light range, to
enable operations inside the human body. Also, the PSD(MS)
should be very high, to enable efficient switching-off of the
activity prior to administration. Again, the scenario shown in
Fig. 3 represents an ideal situation where the PSD(S) is of lesser
importance. In more realistic case, however, the difference
between the two forms is limited, and it is important to achieve
a high PSD of the thermally stable form to observe a difference
in the biological system being regulated.
Photoswitches that could full all those requirements are P-
type diarylethenes and fulgimides,27 which show absorbance in
the 450–700 nm region, but the geometrical changes that can be
obtained upon isomerization are limited, which renders the
design of diarylethene-containing photocontrolled tools for
biomedical application challenging.13,28 Tetra-substituted azo-
benzenes could also be a possible candidate for this scenario, asChem. Sci., 2020, 11, 11672–11691 | 11677
Fig. 6 (a) Azosulfonylurea 2 used for the control of pancreatic beta cell function. (b) The UV-spectrum of compound 2 in the dark (black line) and
under irradiation with 520 nm light (green line) (c) cycles of photoswitching between cis- and trans-2, with in green irradiation with 520 nm and in
black under dark conditions. (d) Rodent islets treated with compound 2, under dark or under light (560 nm) conditions, the response is increasing
of insulin secretion. No difference was obtained between dark conditions and the control (Con, 5 mM glucose-alone). Reproduced from ref. 25



























































































View Article Onlinethey show absorbance in the green light region of the spectrum
and half-lives in the days regime.29,30
Although this scenario is not ideal, due to the needed deac-
tivation before administration, it is oen the only option in cases
where the stable isomer shows a higher activity. An example has
been presented by the group of Trauner,31 who used molecule 3
(Fig. 7a) as a photoswitchable blocker of the voltage-gated
potassium channel. While trans-3 was the more potent isomer,
thanks to the considerable thermal half-life of the cis isomer and
the high (>80%) PSD(MS) that can be reached under l¼ 380 nm,
it was possible to generate this form rst, and then use light of l
¼ 500 nm to switch it to the more portent form. While this
example does not yet provide the possibility to use red light for
switching in both directions, it efficiently shows the level of
control (Fig. 7a) that can be achieved using scenario 3.
Furthermore, an alternative approach was recently developed
for azobenzene-based agents that show higher activity in their
stable form. This strategy, dubbed “sign inversion”, relies on
other photoswitches, such as hemithioindigos32 and diazo-
cines33,34 (cyclic azobenzenes) (Fig. 7b). Especially the latter offerFig. 7 (a) Photoswitchable blocking of voltage-gated potassium
channels by compound 3, which shows higher potency in the trans
state, as an example of compounds useful in scenario 3. Reproduced
from ref. 31 with permission from Wiley-VCH, Copyright 2009. (b)
“Sign inversion” approach used when the more potent photoisomer (in
red) is showing higher thermal stability. (c) The potassium channel
blocker/opener diazocine 4 designed through “sign inversion”
approach by Trads et al.33
11678 | Chem. Sci., 2020, 11, 11672–11691an elegant alternative to linear azobenzenes, since their cis form,
whose geometry denes the biological activity, is the thermally
stable one. This is due to the fact thatmost active azobenzenes are
in the elongated stable form (the trans isomer), while in diazo-
cines the thermally stable-isomer (cis) is bent.33,34 An illustrative
example was shown by Trads et al. (Fig. 7c), who used function-
alized diazocines as potassium channel blockers/openers.33 The
design was based on prior observation that classical azobenzene-
modied molecules showed higher potency in the trans form (see
compound 3). The use of diazocine (compound 4) resulted in the
trans form still being more potent, but in this case thermody-
namically less stable, enabling transient photoactivation of the
stable cis form upon irradiation with 400 nm light.333.4 Scenario 4
In this scenario, the photoresponsive molecule is administered
in its inactive, thermally stable form. At the target site, it is
activated by irradiation at l1, while irradiation of the
surrounding tissues at l2 results in the decrease of activity
outside the intended site of action.
In this case, the metastable form is the one that shows
higher activity, however, its long half-life is not a limitation, in
fact it can help in achieving a high PSD(MS). The key require-
ment in scenario 4, which severely limits the repertoire of
photoswitches suitable for it, is for both of the isomers to be
addressable in the red/NIR light. Fig. 8 further elaborates on the
critical properties of photoswitches used in scenario 4 (Fig. 8a).
Insufficient forward (Fig. 8b) and backward (Fig. 8e) switching
cross sections cause the insufficient exposure of target and
harmful exposure of the body to the active compound, respec-
tively. Low PSD(MS) (Fig. 8c) may result in limited biological
effect increase under irradiation, especially when the difference
in potency of photo-isomers is small. Finally, low PSD(S) leads
to the exposure of the body to the active form.
Photoswitches that full these requirements are scarce,
since the necessity for the both isomers to absorb in the red/NIR
region of the spectrum with good band separation poses
a challenge hitherto unmet. Promising systems include indigo
switches,8 diarylethenes,13 tetra-ortho-methoxy-substituted azo-
benzenes29 and azonium compounds35 as long as the photo-
switch can be fully or almost fully switched to its less potent
state.This journal is © The Royal Society of Chemistry 2020
Fig. 8 Key photoswitch parameters for scenario 4. (a) Light- and
temperature-induced changes in the content of the metastable, bio-
logically active isomer (ideal situation). In panels (b–e), consequences
of insufficient forward photoswitching cross section (panel b), PSD(MS)
(panel c), PSD(S) (panel d) and insufficient backward photoswitching



























































































View Article OnlineThis is an ideal scenario, where the photoresponsive mole-
cule upon administration does not show any activity and can be
activated with spatial and temporal control with light. An
example of this was reported by Herges and co-workers (Fig. 9).
The photoresponsive MRI contrast agent (compound 5) is active
in the cis form (MS), resulting in faster magnetic relaxation of
surrounding protons, while when the photoresponsive contrast
agent is in the trans form, no MRI contrast is observed. The
contrast could be switched on, upon irradiation with 505 nm
light, and needs to be switched off with 435 nm light due to the
long half-life of 39 days (in water at 37 C). Although this
example does not yet full all the requirements of this scenario,
as the activation wavelength in the red/NIR light is still lacking,
it shows a promising starting point for further optimisation.36,37
3.5 Scenario 5
In the nal scenario (Fig. 3), the photoresponsive molecule is
activated aer administration to the human body. However, in
this case, the activation is irreversible – either due to the natureFig. 9 The photoresponsive MRI contrast agent 5. In the trans isomer sh
cis isomer the contrast is switched on. This process can be reversed by irra
from PCCP Owner Societies, Copyright 2019.
This journal is © The Royal Society of Chemistry 2020of photoresponsive agent (PPG vs. photoswitch) or due to the
process being triggered (e.g. an irreversible cargo release).
Again, an important parameter is the activation wavelength,
since the activation is envisioned to be inside the human body.
Other key points include (i) the stability of the caged prodrug,
because premature release can lead to undesired side effects
and (ii) the uncaging efficiency, since aside from being
responsive to red light activation, the photoresponsive unit
should feature high quantum yield of the uncaging process for
this process should not require long irradiation times.20,38
This relatively simple, yet powerful approach has been used
to enable local drug activation (Fig. 10a and c) and release
(Fig. 10d–g). An important application for this scenario is the
use of photocaged (PPG-modied) bioactive compounds, where
the part of the compound, which is crucial for its biological
activity, is blocked with a PPG and upon photocleavage the
compound becomes active (Fig. 10a and b). An example of this
was reported by Bliman et al., where a PPG was incorporated
into a proto-oncogene tyrosine-protein kinase (RET) inhibitor
(compound 6).39 RET is involved in the development and
maintenance of neurons of the central and peripheral nervous
system. The authors protected the amine functionality, and
upon irradiation with l ¼ 365 nm light, the inhibitor 6 was
released showing a 12-fold increase in potency. The uncaging of
the inhibitor was also performed in vivo (zebrash embryos)
and was shown to effect motoneuron development (Fig. 10b).
Sitkowska et al. recently showed how low energy red light can be
used for controlling biological activity, by reporting a BODIPY-
protected dopamine derivative (Fig. 10c, compound 7). The
light depended release of compound 8 was tested in sponta-
neously beating hESC-derived cardiomyocytes, upon irradiation
with 652 nm light for 1 min, there was an increase in heart beat
frequency observed.40
Applications of scenario 5 in drug delivery41 can be achieved
by constructing drug carriers that feature light responsive
release systems (Fig. 10d and g), or whose structure integrity is
responsive to light (Fig. 10e). The example of the rst approach
(Fig. 10d) employs of red-light-responsive tetra-ortho-methoxy-
azobenzene photoswitches, which form supramolecular inter-
actions with b-cyclodextrins to create a cap on the silica nano-
particles loaded with cargo. Red-light-induced trans–cisows no MRI contrast, while upon isomerization with l ¼ 505 nm to the
diation with l¼ 435 nm light. Reproduced from ref. 37 with permission
Chem. Sci., 2020, 11, 11672–11691 | 11679
Fig. 10 Examples of application of scenario 5 in drug activation, delivery and medical imaging. (a) PPG-protected proto-oncogene tyrosine-
protein kinase (RET) inhibitor 6, which prevents motoneuron extension and axonal pathfinding during development in zebrafish. (b) Quantifi-
cation of axonal phenotypes in the different treatments with compound c6 (caged-6) and 6 in different concentrations and with different post
fertilization (hpf) incubation times (n ¼ number of axonal processes quantified). Reproduced from ref. 39 with permission from Springer Nature,
Copyright 2015. (c) BODIPY-protected dopamine derivative activation for controlling heart rhythm. (d) Light-responsive supramolecular valves
for photocontrolled drug release from mesoporous nanoparticles. Reproduced from ref. 42 with permission from the American Chemical
Society, Copyright 2016. (e) Supramolecular block copolymers as novel UV and NIR responsive nanocarriers based on a photolabile coumarin
unit. Reproduced with permission from ref. 44 from Elsevier, Copyright 2020. (f) A light-responsive liposomal agent for MRI contrast
enhancement and monitoring of cargo delivery, showing the increase of fluorescence intensity upon light-induced release of model cargo.
Reproduced from ref. 45 with permission from The Royal Chemical Society, Copyright 2019. (g) Left: furyl-substituted DAE undergoes retro-
Diels–Alder upon ring opening under irradiation with l ¼ 400 nm light, resulting in a release gradual of compound 13. Right: the gradual release
rate of maleimide (13) can be reversibly activated by switching compound 11 to its open form with l ¼ 400 nm light and back to the closed form



























































































View Article Onlineisomerisation of the switch results in the loss of interactions
with the cap and therefore in the cargo release.42 The concept of
using photoswitches for uncaging on molecular level was
further exploited by Göstl and Hecht who designed a furyl-11680 | Chem. Sci., 2020, 11, 11672–11691substituted diarylethene 11 (Fig. 10g). Upon irradiation with l
¼ 400 nm light, compound 11 switches from its closed to open
form, which enables the release of compound 12 and mal-



























































































View Article Onlinereaction could be reversibly switched off again by closing the
diarylethene back to its unreactive form.43
Another drug carrier approach (Fig. 10e) is represented by
the use of amphiphilic block copolymers that featured a light
responsive, coumarin-based PPG incorporated into the side
chain. The block copolymers were able to self-assemble into
micelles of about 25 nm diameter when dispersed in water,
trapping the cargo. Upon irradiation with 365 nm light, the
micelles disassembled. This effect could also be achieved under
irradiation with NIR light (730 nm), using two-photon absorp-
tion phenomenon, albeit withmuch lower efficiency (Fig. 10e).44
Finally, the use of scenario 5 in medical imaging-guided drug
delivery was reported by Reebing et al. Here, a Gd3+-based MRI
contrast agent 10 was linked via a PPG to lipophilic alkyl chain
(resulting in compound 9), which could dock into DOPC-based
liposomes (Fig. 10f). These liposomes could be lled with cargo,
and upon irradiation with 400 nm light the cargo could be
released, with the simultaneous change in the size of the
contrast agent, which could be followed by MR imaging to prove
efficient photoactivation.45 The examples above illustrate the
applications of scenario 5, however they do not yet full all the
requirements stated above, especially with respect to red light
activation and/or high uncaging efficiency. However, they
represent a promising set of proofs-of-principle that will inspire
further applications of this relatively most simple, yet powerful
approach.4. Shifting the photoresponsive
molecule activation wavelength to the
red/NIR range
In all the scenarios described above that rely on the local acti-
vation in human body, the wavelength of light used for this
purpose is of crucial importance, since light needs to penetrate
deep through the skin and into tissues in order to reach the
photoresponsive molecules. The preferred activation wave-
length is between 650–900 nm (red light to near infrared
light).18,19,46 Although most of the photoresponsive molecules
used today are activated with UV light (see also the examples
above), in recent years a considerable amount of research has
been performed to bathochromically shi the absorption
bands. In the following sections, we summarise the strategies
that are taken towards shiing the activation wavelength to red/
NIR light. The approaches taken in enabling the visible light
activation fall generally into three categories: (i) changing the
band gap in the photochromic unit itself, (ii) taking advantage
of two-photon absorption processed, and (iii) using indirect
photoexcitation through energy of electron transfer.47 Since the
rst approach is the most specic to the photochromic tools, we
discuss it below in more detail.
The rst strategy taken to enable direct excitation at higher
wavelengths is the increase of p-conjugation in the chromo-
phore, which leads to the increase in HOMO and decrease in
LUMO energy levels. This general approach is applicable to all
chromophores. Tosic et al. have reported its use for diary-
lethenes, which were modied increase the conjugationThis journal is © The Royal Society of Chemistry 2020(Fig. 11a, compounds 14–17), which lead to bathochromically
shi of the absorption band (from 300 nm to 420 nm).48 Zweig
et al. reported different p-extended pyrrole hemithioindigo
photoswitches (Fig. 11a, compounds 18–21), where the stilbene
core was replaced by a pyrrole, which increased already the
activation wavelength, while arylation of the pyrrole increased it
even further.49,50
The increase in conjugation can also be applied to shi the
activation wavelength of various PPGs, as was shown by Bojtár
et al., who reported coumarins containing a heterocycle moiety
which included a quaternary nitrogen atom (Fig. 11b,
compounds 22–24). Besides increasing the activation wave-
length, the charge also increase the solubility in aqueous
solvents.51 Another example of the use of increase p-conjuga-
tion was reported by Peterson et al., who presented BODIPY-type
PPGs that were conjugated with styryl groups (Fig. 11b,
compounds 25–27), allowing operation above 700 nm.52
However, increasing the p-conjugation is not always effi-
cient, as was shown by Irie and co-workers, who aimed to
bathochromically shi the absorption spectra of diarylethenes.
While promising results were obtained when increasing the p-
conjugation with a perylenemonoimide (PMI) and per-
ylenediimide (PDI) dye on the R position (Fig. 11c, compound
29 and 30), when introducing the same substituents at the R0
position at the aromatic ring (compounds 31–36), the diary-
lethene lost its photoswitch ability.53 Increasing the p-conju-
gation can also be applied on azobenzenes, where it results in
shiing the p–p* transition band, commonly used to evoke the
trans–cis isomerisation.47 However, this can result in overlap
with the lower energy n–p* band, which is used to induce the
reverse cis–trans isomerization, making it harder to switch the
isomers selectively.47 Altogether, increasing the conjugation is
a general approach that oen provides the desired effects.
However, it also commonly results in the decrease of aqueous
solubility and has thus limited application in biomedical
context.
Another strategy used to enable direct excitation with light of
lower energy is to take advantage of the so-called push–pull
substitution pattern, in which a strongly electron donating and
withdrawing molecules are placed in conjugation on the chro-
mophore. While oen used for azobenzene-based dyes, it is also
efficient in increasing the activation wavelength of hemi-
thioindigo photoswitches. Here, the thioindigo fragment can be
seen as the acceptor moiety, while the stilbene acts as the donor
part. This effect can be enhanced by increasing the stilbene
donor capacity through substitution.9 However, this can lead to
decrease of thermal stability of the trans-isomer.54 Kink et al.
reported an increase activation wavelength by increasing the
donating effect by introducing a substituent on the para posi-
tion of the stilbene group (Fig. 12a, compounds 37–42)55, and
upon protonation of the amine this donating effect can be
switched off.
On one hand, using push–pull systems is a viable option for
applications in aqueous environment, because the resulting
chromophores show highly pronounced solvatochromism and
the band-shiing effect is stronger in polar media.47,56 On the
other hand, however, it also commonly results in a decrease ofChem. Sci., 2020, 11, 11672–11691 | 11681
Fig. 11 Extension of the p-conjugation as a method to red-shift the activation wavelength of molecular photoswitches (a and c) and photocages
(b).
Fig. 12 Introduction of electron withdrawing and donating substituents in conjugated positions in photoswitches to create a “push–pull” system



























































































View Article Onlinethe thermal stability of the metastable form of the photo-
switchable molecule. This strategy is therefore particularly
useful in scenario 2, where short half-lives and red-shied
activation wavelengths are crucial, as shown by Trauner and
co-workers in the photocontrol of pancreatic beta cell function
with molecule compound 3 (Fig. 6).25 Compound 2 could be
switch with 560 nm to the active cis form (compound 2, with
a half-live in sub-second range), which binds to Epac2A,
allowing optical control of cell function and insulin secretion.
Another approach that is used to engineer the position of the
bands is through complexation using electron pairs in the
chromophore. Aprahamian and co-workers reported azo-
benzenes with a complexation of the azo group to BF2, which11682 | Chem. Sci., 2020, 11, 11672–11691lead to bathochromic shi the p–p* band. Further optimiza-
tion of the R group (Fig. 12a, compounds 43–45) enabled the
isomerisation with red light of 730 nm.57
Finally, a strategy that has proven especially useful for
designing visible light responsive azobenzenes in recent years
relies on the use of lower energy transitions – namely the
absorption bands associated with the symmetry-forbidden n–
p* transitions. In normal azobenzenes, those bands have low
intensity and are poorly resolved for both isomers, and are
therefore used only for reverse cis–trans switching, taking
advantage of the usually higher quantum yield for this transi-
tion over the forward one. However, increasing the n–p* band



























































































View Article Onlinephotoisomers, has enabled many successful designs that are
already used in biomedical context. The rst use of this strategy
dates back to the discovery of the photochemistry of diazocines
by Herges et al., where the band separation was achieved
through geometrical constrain, which also lead to inverse
thermal stability58 (also explained in Section 3.3). Later, Woolley
and co-workers reported a tetra-ortho-methoxy substituent
pattern for azobenzenes to separate the n–p* transitions by
bathochromically shiing the band of the trans isomer
(Fig. 12b, compounds 46–48).59 The authors hypothesized that
this was due to the twisting of the trans-isomer and due to the
interaction of the methoxy groups with the lone pair of the
nitrogen of the azo group. Further increase of the electron
density on the chromophore rendered it basic enough to
undergo protonation at physiological pH, and enabled activa-
tion with NIR light.23 A similar bathochromically shi of the
absorption bands was reported for the tetra-ortho-chloro and
tetra-ortho-alkylthio substituted azobenzenes.29 A complemen-
tary strategy was taken by Hecht, Bléger and co-workers, who
hypsochromically shied the n–p* absorption band of the cis
isomer to achieve better band separation in a tetra-ortho-uoro
substituted azobenzenes, also resulting in a very high thermal
stability of the metastable form.60
Finally, the inuence of substituents on the bathochromic
shi of the absorption bands can me more subtle. For ITI
photoswitch, introducing an electron donating substituents on
the benzene ring at the para position of the nitrogen atom
increases the absorption wavelength. This effect is due to the
change in the twist around the]N–C– single bond: the electron
donating substituents increase the electron density of the
phenyl ring, which leads to an increase in the conjugation with
the thioindoxyl moiety.12 Placing substituents next to the
sulphur atom on diarylethenes also has effect on the activation
wavelength. Pu et al. reported diarylethenes baring different
substituents next to the sulphur (Fig. 12b, compounds 49–54).
The authors showed that electron-withdrawing substituents
increase the activation wavelength and also increase their
cyclization quantum yield, while electron donating substituents
increased the molar absorption coefficients.61
In summary, it needs to be stated that although the above
mention strategies are promising, it is a daunting task to
increase the activation wavelength of the photocontrolled
molecular tools without severely affecting their other key
properties (absorption band separation, half-life of the meta-
stable form and pharmacological properties) and each of the
new designs needs to be re-evaluated taking into account all
these aspects.Fig. 13 Overview of photoresponsive molecules discussed in the
engineering of photostationary state distributions (PSD).5. Improving photostationary state
distributions for molecular
photoswitches
Obtaining a large difference in biological activity between
isomers is not readily achieved, and incomplete photo-
isomerization to either the stable or metastable photo-isomer
adds a photochemical challenge to acquire large differencesThis journal is © The Royal Society of Chemistry 2020in biological activity. As described in Fig. 2, PSD in the forward
switching direction is dened by the ratio of 3(S, l1)  fS/MS
and 3(MS, l1)  fMS/S and therefore is inuenced by the
absorption band overlap.
Most of the known photoswitches cannot be quantitatively
switched between the two forms using light, which presents
a major challenge to the efforts on increasing the activation
wavelength (see Section 4 and discussions on band separation
therein). However, over the years some strategies have been
reported to increase band separation and help optimize the PSD
achievable for switching in both directions.
For classical, UV-responsive azobenzenes, an empirically
established62,63 design principle is the introduction of alkoxy-
substituents in the para position, resulting in >90% efficiency
of switching in both directions due to the efficient separation of
p–p* bands. For the visible-light responsive systems that rely
on n–p* transitions, the aforementioned use of ortho-
substituted azobenzenes, especially the uorine substituted
ones (Fig. 13, compound 55), results in high PSD ratio (90% cis
under 500 nm irradiation, 97% trans under 410 nm irradia-
tion).60 Furthermore, diazocines are known to feature large
separation between the cis and trans n–p* transitions. For an
example molecule 56, used by Woolley and co-workers to pho-
tocontrol peptide conformation, the authors reported to be able
to almost fully (99.7%) isomerize it back to the thermally stable
cis form with 518 nm light.64
Petermayer et al. reported that, while increasing the activa-
tion wavelength by increasing the push pull system of the
hemiindigo (compounds 57–61, Fig. 13) with amine substitu-
ents on the stilbene moiety, as well as placing substituents in
the nitrogen from the indigo part, they also obtained high PSD
and long half-lives (in the day to year range). For compound 61,



























































































View Article Onlinethan 95% of the trans isomer was formed, while with irradiation
with 680 nm, 99% was converted back to the cis isomer. The
high PSD and half-lives are not compromised if the nature of
the solvent is changed (from toluene to THF to DMSO). These
properties are due to the conformational differences of the cis
and trans isomers, where full planarity and conjugation of the
chromophore can be achieved only in the trans isomer.656. Engineering the half-life of the
metastable state
The stability of the metastable state is the nal parameter that
denes the suitability of molecular photoswitches for different
scenarios Fig. 3. While both short and long-living species have
their applications, it is important to be able to understand the
factors that inuence the thermal stability to be able to engineer
it to one's needs.
For azobenzenes and heteroaryl azo dyes, the inuence of
substituent on the half-life are the best understood,66 which
enables the adjustment of this property from nanosecond, in
extreme cases of push–pull systems (see molecules 62–65),67 to
years.60 The latter has been achieved in case of tetra-ortho-uoro
substituted azobenzenes, which, besides enabling visible-light
activation, also lead to a higher stability of the cis isomer, due
to the stabilization of its n orbital, while the n orbital of the
transition state is less stabilized, which leads to a higher barrier
for the cis to trans isomerization. Knie et al. demonstrated this
for compound (Fig. 13, compound 55), which showed half-life of
two years in DMSO.60 Another photoswitch that is known to
possess extremely high thermal stability of the metastable
isomer is the hydrazone structure (Fig. 14, compounds 66–69),
reported by the group of Aprahamian.11 Those molecules
feature half-lives in the centuries timescale and can be
considered to be bistable for all practical purposes.
As discussed in Section 4, the push–pull strategy applied to
HTI can negatively inuence the half-life and PSD of the HTI,
due to a decrease in thermal stability of the metastable isomer.
However, this can be prevented by placing electron-donating
groups on the para position of the sulphur atom, which stabi-
lize this form. An example of this was shown by Kink et al.,Fig. 14 Overview of the photoresponsive molecules to discussed for
engineering the half-life.
11684 | Chem. Sci., 2020, 11, 11672–11691where an amine moiety was placed para to the sulphur (Fig. 12,
compound 42), the obtained HTI showed increased half-life (up
to 30 days) and enabled reaching the PSD for each isomer of was
around 80%.55,68 Hecht and co-workers described an approach
to increase the half-life of N,N-disubstituted indigos (Fig. 14,
compounds 70 and 71), an emerging class of promising pho-
toswitches that can be activated by red light, but still suffer from
stability issues in aqueous media. By incorporating electron
withdrawing substituents on the aromatic rings (Fig. 14,
compound 71), the thermal stability of the metastable cis-
isomer could be increased (half-life from 3.1 min to 408 min),
while the switch could still be operated with 660 nm light and
its stability in water was improved.24 Recent studies also showed
an improvement on the half-lives of spiropyrans. Abeyrathna
et al. reported that by incorporating an indazole ring instead of
the phenol (Fig. 14, compound 72), the PSS and also the half-life
(to 48 h) were both enhanced.69
Altogether, the recognition of the importance of half-life as
the key parameter that dened the application area of photo-
controlled tools has inspired many recent reports on controlling
this property. While it is still intertwined on a molecular level
with absorption band separation and position, rendering the
selective optimisation of half-life without affecting the lmax and
PSS a major challenge, continued research on structural ne
tuning supported by calculations might enable this in the
future.7. Pharmacological properties of
photocontrolled molecular tools
At the current early stage of the development of photo-
responsive molecules for applications in medicine, the focus
oen lies on maximising the difference in behaviour between
the irradiated and non-irradiated molecules (see Section 3). The
recognition of the importance of the colour of light for the
penetration depth has also driven the development of new
molecular tools (see Section 4). Those two factors represent of
course condiciones sine quibus non for future applications.
However, pharmacological factors,70 such as stability in water
and cellular environment, polarity and toxicity are also key
parameters that will have to be addressed in the future before
the light-controlled molecules can make it to the bedside.
Furthermore, they can positively inspire new approaches, where
for example two photoswitches that operate in unison are
applied:71 one for controlling the interaction with the molecular
target (pharmacodynamics), and one for controlling the phar-
macokinetic properties of the photoresponsive construct, to
inuence its ADME prole. In the following sections, we
summarise the recent efforts towards studying and optimising
these parameters for PPGs and molecular photoswitches.7.1 Stability in water and in the cellular environment
In general, our understanding of the aqueous and metabolic
stability of molecular photoswitches and PPGs is only being
developed in recent years. An exception to this are the azo-



























































































View Article Onlineand clothing industries for many years.72 This has resulted in
comprehensive knowledge of their behaviour and interactions
with biomolecules. Azobenzenes are degraded through reduc-
tion with glutathione (GSH) or via enzymatic metabolism.19,29,73
Since the resulting anilines are toxic,74 special care needs to be
taken to test for the susceptibility of designed azobenzene
photoswitches towards GSH reduction.73,75,76 For example,
compound 74 (Fig. 15) is a derivative of combretastatin A-4
(compound 73), which is a colchicine domain MT inhibitor,
whose isomerisation from its trans to cis form is accompanied
with impressive and rarely observed 250 increase in potency,
as reported rst by Borowiak et al.,77 followed by and Engdahl
et al.78 However, further investigation by Sheldon et al.79
revealed that compound 74 was prone to GSH degradation and
that the light activated cis-isomer degraded faster than the
trans-isomer.77–79
The susceptibility of azobenzenes to reduction by GSH
depends strongly on their substitution pattern. Since the reac-
tion is initiated by a nucleophilic addition of the GSH thiol
group to the diazo moiety,80 increasing the electron density on
this bond lowers the reduction rate. Several examples illustrate
this effect. Stricker et al. introduced an electron rich pyrazole as
one of the aromatic rings in a diazo molecule. The resulting
arylazopyrazoles were stable when incubated with GSH for 22 h
(Fig. 15, compound 75–81).75 Woolley and co-workers showed
that a para substituted electron rich azobenzene 82 (Fig. 15),
which was used as uorescent reporter in zebrash embryos
showed no signicant changes in the UV-Vis spectrum or in the
thermal relaxation rate aer the incubation of the azobenzene
with GSH for 24 h.81
However, a balance needs to be found when increasing the
electron density to prevent GSH reduction, since beyond
a certain point it will render the diazo bond Brønsted-basic
enough to be protonated at physiological pH, again increasing
the sensitivity towards degradation.19,29,73 This was observed by
Woolley and co-workers,73 who synthesized multiple tetra-ortho-
substituted azobenzenes with the aim to bathochromically shiFig. 15 Overview of discussed photoswitches for the stability in water a
This journal is © The Royal Society of Chemistry 2020the n–p* absorption band of the trans isomer (Fig. 12,
compound 48 and Fig. 15, compound 83). And observed that the
azobenzene with the more electron-donating methoxy substit-
uent was degraded upon incubation with GSH. The authors
concluded that the tetra-ortho-methoxy azobenzene was more
easily protonated, which increases the electrophilicity of the azo
bond. A later publication by the same authors showed how to
prevent the degradation while still maintaining benecial
photochemical properties: aer changing the methoxy substit-
uents to alkylthio substituent (Fig. 15, compound 84), the azo-
benzenes proved to be stable against GSH, while the wavelength
absorption was still increased.73,76
Importantly, it is not only GSH that can reduce the diazo
bond in biological assays. A degradation of the azobenzene
through a different pathway was reported by Scher et al., who
studied 2-aza-thiazole-based compounds 85–87 as photo-
switchable inhibitors of kinases p38aMAP kinase and casein
kinase 1d (CK1d). In the in vitro kinase assay, compound 86
showed higher activity in its cis-form, which did not correspond
to the prediction from the in silico docking studies. Aer further
investigation, supported by crystal structures of the switches
bound to proteins, the authors identied the reduced hydrazine
form of compound 86 as the potent inhibitor. However, in this
particular example, dithiothreitol (DTT), which is commonly
added to prevent oxidation of the protein in the kinase assays,
was responsible for the reduction. Since cis-isomer is more
prone to reduction than the trans-isomer, the active hydrazine
was present in higher concentration in the irradiated sample,
explaining the observed higher potency.82 Again, using a more
electron rich, N-methyl-imidazole-based analogue 87 prevented
the reduction, highlighting the feasibility of this approach.
As opposed to azobenzenes, other molecular photoswitches
and PPGs have been much less studied with respect to their
stability in biological context. However, it is known that spi-
ropyrans in their merocyanine (MC) form are prone to hydro-
lysis, since water can easily attack the ene-iminium cation,
which is followed by a retro-aldol reaction (Fig. 15, compoundnd in the cellular environment.



























































































View Article Online88–90), resulting in degradation, as was reported for compound
88. To reduce this problem, over the last few years spiropyrans
have been developed that are more stable against the hydro-
lysis.83–85 An example has been presented by Heckel and co-
workers, who reported that the hydrolysis can be almost
entirely prevented by replacing the nitro-phenol ring by pyri-
dine (compound 91) or N-methyl pyridinium (compound 92)
ring (Fig. 15).83,85 The increased stability against hydrolysis is
most likely due to the fact that the thermal equilibrium lies to
the spiropyran side.
The importance of stability under physiological conditions
has also been recognized for PPGs. Since their stable attach-
ment to the caged molecules in the dark is the prerequisite for
successful application, their optimisation has also been
focussed on this aspect. For example, in an effort to improve
stability for ortho-nitrobenzyl (oNB) protecting groups, Zaitsev-
Doyle et al. found that the methylenedioxy substituted PPG 94
was more stable towards hydrolysis then compound 93.86 A
completely different approach to improve stability was shown
by Carling et al. paclitaxel, dexamethasone, and chlorambucil
where caged with amino-1,4-benzoquinone. However, since this
protecting group is not stable in aqueous media, the authors
incorporated the unstable photocaged compound 95 in water-
dispersible nanoparticles. This way, the amino-1,4-
benzoquinone PPG was protected by the hydrophobic core of
the nanoparticles from being degraded (Fig. 16). Upon light
irradiation with 590 nm, the caged compound was released.87
Altogether, stability in biological context poses and impor-
tant design criterion for photoresponsive tools, which has
recently stimulated research addressing this particular issue. It
is important to test the stability in early stages to be able to
make design changes to prevent this.7.2 Toxicity
Before photoresponsive molecules can enter clinical trials and
be used in medical applications, it is necessary to perform in
vivo toxicity studies.88 The extent of these toxicity studies will
depend on the target amount to be injected. E.g. for micro-
dosing studies in humans, the initial toxicity tests may be
limited. Doses above the microdosing range of 100 mg will
require more elaborate investigations.89
However, since the majority of the designed photoresponsive
molecules fails to reach that state, the general knowledge on
their toxicity is low. Importantly, sometimes the toxicity coin-
cides with the desired bioactivity, as is the case in chemo-
therapy. This is being taken advantage of in the eld ofFig. 16 Overview of discussed PPGs for the stability in water and in the
reproduced from ref. 87 with permission from The Royal Society of Che
11686 | Chem. Sci., 2020, 11, 11672–11691photoactivated chemotherapy (PACT),90 where both the PPG,
which here is a metal complex, and the caged chemotherapeutic
become toxic upon activation. However, since in most cases the
photoresponsive element itself if required to be non-toxic, we
focus here on general undesired toxicity of photocontrolled
tools.
Because azobenzenes have been used for various purposes,
including food dyes, for decades, most information about their
toxicity is available.72,74 While, as a class of compounds, they do
not show general toxicity, azobenzenes are known to be
degraded by enzymatic metabolism. Thus great care has to be
taken to prevent degradation via bacterial azoreductases or by
intestinal microora, which break the azobenzenes down to
anilines. It is therefore important to test not only the azo-
benzene for toxicity but also their corresponding metabo-
lites.72,74 Furthermore, as signalled before, it would be benecial
to develop molecules with a second photoswitch that regulates
the metabolism aer being pharmacologically active to prevent
toxic reactions and improve efficient removal from the body.
Chung and Cerniglia reported that the anilines that result
from azobenzene degradation can be further metabolized to
genotoxic compounds. They studied the structures of many
mutagenic azo dyes and found that compounds containing p-
phenylenediamine and benzidine moieties where especially
mutagenic. They also reported that for p-phenylenediamine the
toxicity can be decreased by sulfonation, carboxylation, deam-
ination, or via substitution of one of the hydrogen of the amino
group by ethoxy or an acetyl group. For the benzidine moiety, it
was found that complexation with copper ions or formation of
salts decreases the mutagenicity.91
Recently, Babii et al. published a toxicity study of diary-
lethene photoswitches (Fig. 17). The diarylethene was incorpo-
rated into a cyclic peptide gramicidin S (96), which has been
designed for exhibiting anti-cancer properties.92 The authors
observed a difference in the cytotoxicity in vitro between the
closed and open form of compound 97. However, when the
same study was performed in vivo, the difference in cytotoxicity
between the open and close form was reduced. It was hypoth-
esized that this is due to the fact that the closed form has less
favoured pharmacokinetics. Aer administration, the closed
form was detected in kidney, liver and blood plasma in high
concentrations. The authors also investigated phototoxicity of
the photoswitchable drug. They saw that half of animals kept in
the dark showed signs of toxicity up to 2 hours aer treatment,
while the animals in daylight showed toxicity signs at least till 6
hours aer the treatment. These ndings highlight the impor-
tance of performing in vivo toxicity tests.cellular environment. For compound 95, the accompanying figure is
mistry, Copyright 2016.
This journal is © The Royal Society of Chemistry 2020



























































































View Article OnlineIn the design of PPGs, toxicity plays an important part
because the removed cage should not show general toxicity.18,93
It is known that oNP-based PPGs can form harmful by-products
upon photocleavage (Fig. 17, compounds 98 and 99).18 An
example for preventing the formation of those by-products was
shown by Young and Deiters.94 Different PPGs blocking the 9-
NH position of theophylline where tested. By changing the PPG
to (2-nitro-valery)oxymethyl (NVOM) (Fig. 17, compound 98b),
the authors prevent the formation of toxic benzaldehyde.
Instead, acetophenone is released upon uncaging, which is
known to be more benign. Due to the high risk of toxicity, it is
important to test it for the photoresponsive molecules as soon
as possible aer the proof-of-concept for an application is
shown. Oen, it is preferred to perform such test also in animal
models or organoids, as preliminary test in single cells cultures
do not adequately model metabolism in humans.95,967.3 Solubility
A balanced solubility is a key parameter in the development of
effective bio-active molecules. Considerations that play a role in
this is whether compounds should be able to pass membranes,
whether therapeutically relevant concentrations can be ach-
ieved and how fast compounds are cleared from the patient.
Frequently solubility is characterized by the log P value,
which describes the partition coefficient of solubility between
a solution at physiological pH and 1-octanol. In addition to this
model, aqueous solubility can also be described as the equi-
librium between a compound in solution and it its most stable
crystal form, hence melting temperature has been a predictor
for solubility. Combining both, the General Solubility Equation
(GSE) describes:97
log Sw ¼ 0.01(Mp  25)  log Poctanolwater + 0.5,
where Sw is molar aqueous solubility of an organic non-
-electrolyte in water and Mp is the melting point (in degrees
Celsius).
Low aqueous solubility of small molecule drugs has been
a challenge for the eld of medically chemistry for decades and
generally two strategies can be derived from the GSE. First, one
can improve aqueous solubility by chemically modifying drug
with solubilizing groups, such as by increasing the number of
hydrogen bond donors and acceptors or adding groups with so
or hard charges. Secondly, one can decrease the melting point
of a compound, for example by removing aromaticity orThis journal is © The Royal Society of Chemistry 2020otherwise decreasing the atness of the compound.98,99 We
recognize that many light-responsive tools are large at
aromatic molecules with poor aqueous solubility, which
severely limits their medical use. Besides solubility reasons,
extension of compound lipophilicity also bear the risk of
accumulation in fatty tissues, and thus enhances the potential
for long term toxicity of the substance in humans.100 Here, we
discuss several examples on strategies to improve aqueous
solubility of light-controlled tools and how these approaches
affect other properties.
A common strategy to increase aqueous solubility is the
addition of polyethylene (PEG) chains. This approach was re-
ported by Dommaschk et al. to improve the solubility of the rst
generation photo-switchable contrast agents for MRI (see
Fig. 18, compound 100), where the contrast agents was switched
off when the azobenzene moiety was in the trans-isomer due to
change in coordination number of the nickel(II).36 However this
design had solubility issues and all measurements where per-
formed in DMSO.36 In a later reported, next generation photo-
switchable contrast agent, the solubility issue was solved by
linking glycerol dendrimers to the porphyrin complex (Fig. 9).
Although the solubility was increased, the switching was less
effective and for some complexes it was found that the nickel
ion was lost from the complex.36,37 This example perfectly
demonstrates that any modication of the original molecule
may cause functional changes hampering essential properties.
Moreover, one needs to be aware on the potential impact of
such changes on e.g. biodistribution of the new compound. In
radiopharmacy, these effects can be shown quite easy, whereas
they may remain unseen during the clinical development of
a photoswitch containing compound. It may even be benecial
to perform biodistribution experiments using for instance 14C
or 11C labelled-molecules, in order to be able to evaluate the
pharmacokinetics and biodistribution of a novel compound.101
By doing this, it can be predicted how suitable the particular
compound will perform in animals and humans.
In general, light-responsive molecules are based on rather
at, aromatic, lipophilic systems. Furthermore, red-shiing of
their absorption bands, while necessary for their application
(see Section 4), oen relies on increasing the conjugation and
leads to even less water-soluble, at aromatic molecules.83 An
example of this challenge, and an elegant solution, was shown
by Rustler et al., who studied photoswitchable antagonists for
the histamine H1 receptor. The authors achieved the bath-
ochromic shi of the absorption band by using a push pullChem. Sci., 2020, 11, 11672–11691 | 11687
Fig. 18 Overview of photoresponsive molecules discussed in the
context of controlling aqueous solubility. (a) Introduction of PEG
chains to improve solubility; reprinted from ref. 36 with permission
from American Chemical Society, Copyright 2015. (b) Introduction of
a solubilizing group to improve solubility. (c–d) Controlling biological
distribution; (e) Modulating biological activity through solubility. (f)
Drug release through light-induced increase in polarity; reprinted from




























































































View Article Onlineazobenzene design (Fig. 18, compounds 101 and 102). However,
this resulted in reduced solubility, which was recovered upon
the introduction of a sulfonate group on the aromatic ring
(compound 102).103 Further examples showing the effectiveness
of adding sulfonate groups for solubility were provided by the
groups of Woolley104 and Feringa.105
Gratifyingly, it is not always the case that when the activation
wavelength is increased it results in solubility issues. Bojtár
et al. showed that, while trying to increase the activation
wavelength of the coumarin PPG by extending the conjugation
with a cationic, N-alkylated pyridine moiety, they also achieved
the improved the solubility (Fig. 11, compounds 22–24).51
However, careful consideration is required when adding
charged functional group(s) to the photoresponsive molecule to
render them more soluble, as this can inuence their ability to
cross biological membranes, which is crucial for altering the
activity of intracellular drug targets. A drug containing a nega-
tive charge such as a sulfonate does not allow for efficient
diffusion passed the cell membrane, while permanently positive
charges such as N-alkylated pyridines tend to accumulate in11688 | Chem. Sci., 2020, 11, 11672–11691mitochondria. Those effects are of course not necessarily
a limitation. Example of turning this effect to an advantage was
reported by Dcona et al. (Fig. 18, compound 103), who modied
a drug with a sulfonate moiety, attached through a photo-
cleavable linker. Due to the presence of a negative charge, this
molecule was not able to enter the cells. However, upon irra-
diation with light (l ¼ 365 nm), the anticancer drug was
released from the linker and crossed the cell membrane.106 In
principle, this strategy can be applied to any cell permeable
drug molecule as long as it has reactive groups to which the
light responsive linker can be attached.106 Another example that
uses charges to regulate the compound biological distribution
dynamically with light was reported by Kand et al. By adding
charged functional groups on the BODIPY-based PPG, they
could achieve the selective targeting to cell organelles (Fig. 18,
compound 104). The authors showed that by adding triphe-
nylphosphonium to the BODIPY high accumulation was found
in the mitochondria.107
Besides structural changes to help improve the solubility,
another important point to keep in mind during the design of
a photoswitchable bioactive system is that both isomers need to
be soluble in aqueous solutions to prevent aggregation,108which
can lead to results that are difficult to interpret and highly
depend on the type of medium, its ionic strength, co-solvents
added, etc. However, change in solubility can also be taken
advantage of. This was shown by Brown et al., who studied
different azobenzenes (Fig. 18, compound 105) and observed
different solubilities for the trans and cis-isomer, the cis-isomer
was in most of the cases more soluble in aqueous media. This
effect can shi the cis–trans equilibrium in favour of the cis-
isomer.109
Another way to turn the change in solubility to an advantage
was shown with DASA photoswitches that, upon photo-
switching, turn form planar, linear, hydrophobic form to
a cyclic, zwitterionic one. Helmy et al. incorporated a mono-
methyl PEG chain into the DASA photoswitch through azide–
alkyne cycloaddition reaction. In aqueous environment, the
resulting molecules of compound 106 self-assembled into
micelles. The micelles could be disassembled through cyclisa-
tion induced with yellow light (l ¼ 570 nm), which changed the
polarity of the molecule (Fig. 18f).1028. Optimisation of photocontrolled
tools: towards applications or towards
assays?
In their development, the activity of biologically active mole-
cules is tested on isolated enzymes,110 cells, ex vivo tissues111 or
model organisms,112 long before a molecule ever might enter
clinical trials. The high demand for predictive pre-clinical
models to evaluate biological activity has resulted in a large
toolbox of biological assays. Yet, we recognize that many of
these tests have been developed prior to the time when light
controlled tools emerged and therefore might not be fully
compatible with testing light-controlled biologically active



























































































View Article Onlinein the title of this section: should we optimise the tools towards
their nal application (see clinical scenarios in Section 3), or
towards the assays that we use to determine their biological
activity? Working towards the real application seems to be the
obvious answer, but it cannot proceed without rst showing the
activity and its photomodulation in vitro.
An obvious example of this dilemma is presented by engi-
neering the half-life of the metastable state. For example, many
cell-based assays rely on overnight incubation, which is
achievable for compounds with long thermal half-lives. Assay-
ing long-living photo-isomers is experimentally much easier
then compounds with short thermal half-lives, even though we
recognize that short half-lives are a desired feature in achieving
high spatial resolution to empower nal applications.
Another challenge comes from the fact that the orthogonality
of light in biology has also been recognized in the development
of biological assays, long before the advent of photo-
pharmacology and related techniques. Many such tests rely on
measuring absorbance63 (e.g. many cell viability assays), uo-
rescence (most enzyme activity assays) or luminescence (cellular
assays using reporters111). Obviously, using such assays to
measure activity of compounds that themselves are photoactive
and photoresponsive poses problems. While solutions are
actively being sought aer from the perspective of photo-
controlled tools (cf. the establishing of GFP-orthogonal micro-
tubule inhibitors by Thorn-Seshold and co-workers),113 it is clear
that also new assaying modalities are required that would
provide short experiments without the necessity of optical input
or readout. In that respect the use of electrophysiological114 and
radiometric assays115 seems advantageous and should be
further pursued in the future.
9. Conclusion
Over the years great progress has been made towards the design
of photoresponsive molecules with the longer-wavelength or
improved half-life, PSD and the pharmacological properties.
Despite these achievements, there are still challenges that
remain to be addressed before the translation to the clinic of
these highly interesting compounds can take place.
Importantly, the broad spectrum of potential applications,
as highlighted here by the scenarios dened in Section 3,
renders it impossible to give one set of desired properties for
a photocontrolled tool. We hope that the considerations pre-
sented here will inspire the development and optimisation of
new molecular photoswitches and PPGs towards different
applications, and we are delighted to observe the signicant
expansion of the light-responsive molecule toolbox in recent
years. While appreciating all the effort put into optimising their
(photo)chemical properties, we also invite the respective
communities to consider the pharmacological aspects of pho-
toswitches and PPGs, to ultimately enable bringing light to the
clinics taking advantage of molecular level precision.
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D. M. Barber and D. Trauner, Angew. Chem., Int. Ed., 2019,
58, 15421–15428.
34 P. Lentes, E. Stadler, F. Röhricht, A. Brahms, J. Gröbner,
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C. Richter, H. Schwalbe, B. Suess, J. Wachtveitl and
A. Heckel, Org. Lett., 2015, 17, 1517–1520.
84 T. Stafforst and D. Hilvert, Chem. Commun., 2009, 287–288.
85 T. Halbritter, C. Kaiser, J. Wachtveitl and A. Heckel, J. Org.
Chem., 2017, 82, 8040–8047.
86 J. J. Zaitsev-Doyle, A. Puchert, Y. Pfeifer, H. Yan, B. A. Yorke,
H. M. Müller-Werkmeister, C. Uetrecht, J. Rehbein,
N. Huse, A. R. Pearson and M. Sans, RSC Adv., 2019, 9,
8695–8699.
87 C. J. Carling, J. Olejniczak, A. Foucault-Collet, G. Collet,
M. L. Viger, V. A. Nguyen Huu, B. M. Duggan and
A. Almutairi, Chem. Sci., 2016, 7, 2392–2398.
88 S. Afonin, O. Babii, A. Reuter, V. Middel, M. Takamiya,
U. Strähle, I. V Komarov and A. S. Ulrich, Beilstein J. Org.
Chem., 2020, 16, 39–49.
89 G. Lappin, R. Noveck and T. Burt, Expert Opin. Drug Metab.
Toxicol., 2013, 9, 817–834.
90 S. Bonnet, Dalton Trans., 2018, 47, 10330–10343.
91 K.-T. Chung and C. E. Cerniglia,Mutat. Res., 1992, 277, 201–
220.
92 O. Babii, S. Afonin, T. Schober, L. V. Garmanchuk and
I. Liudmyla, Future Drug Discovery, 2020, 2, FDD28.
93 A. Y. Vorobev and A. E. Moskalensky, Comput. Struct.
Biotechnol. J., 2020, 18, 27–34.
94 D. D. Young and A. Deiters, Bioorg. Med. Chem. Lett., 2006,
16, 2658–2661.
95 S. A. Saganuwan, Bulg. J. Vet. Med., 2017, 20, 291–318.
96 S. Parasuraman, J. Pharmacol. Pharmacother., 2011, 2, 74–
79.This journal is © The Royal Society of Chemistry 202097 T. Sanghvi, N. Jain, G. Yang and S. H. Yalkowsky, QSAR
Comb. Sci., 2003, 22, 258–262.
98 M. Ishikawa and Y. Hashimoto, J. Med. Chem., 2011, 54,
1539–1554.
99 M. A. Walker, Expert Opin. Drug Discovery, 2014, 9, 1421–
1433.
100 E. Jackson, R. Shoemaker, N. Larian and L. Cassis, Compr.
Physiol., 2017, 7, 1085–1135.
101 H. H. Boersma, I. H. Liem, G. J. Kemerink,
P. W. L. Thimister, L. Hofstra, L. M. L. Stolk, W. L. Van
Heerde, M. T. W. Pakbiers, D. Janssen, A. J. Beysens,
C. P. M. Reutelingsperger and G. A. K. Heidendal, Br. J.
Radiol., 2003, 76, 553–560.
102 S. Helmy, F. A. Leibfarth, S. Oh, J. E. Poelma, C. J. Hawker
and J. R. De Alaniz, J. Am. Chem. Soc., 2014, 136, 8169–8172.
103 K. Rustler, S. Pockes and B. König, ChemMedChem, 2019,
14, 636–644.
104 Z. Zhang, D. C. Burns, J. R. Kumita, O. S. Smart and
G. A. Woolley, Bioconjugate Chem., 2003, 14, 824–829.
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